A novel vaccine for Lyme disease led to the production of antibodies against the borrelia organisms that cause the disease in the U.S. and Europe, without sparking major side effects, according to new research. The vaccine must undergo Phase III trials, but the research team is hopeful it will become a tool to help prevent Lyme disease in people. Dogs and humans contract Lyme disease from ticks, and the incidence of Lyme disease in the U.S. is increasing.

Full Story:
Medical News Today

Related Summaries